Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size

Yoshihiro Nishimura\textsuperscript{1,2}, Maiko Taguchi\textsuperscript{1}, Takaumi Nagai\textsuperscript{1}, Masashi Fujihara\textsuperscript{1,2}, Shigeru Honda\textsuperscript{2}, Mamoru Uenishi\textsuperscript{1}

\textsuperscript{1}Department of Ophthalmology, Mitsubishi Kobe Hospital, Kobe, Japan; \textsuperscript{2}Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan

\textbf{Purpose:} To compare the effect of pegaptanib versus ranibizumab on exudative age-related macular degeneration (AMD) with small lesion size.

\textbf{Methods:} This is a retrospective study of 81 eyes from 78 patients with exudative AMD treated and followed up over 12 months. Patients with baseline best corrected visual acuity (BCVA) under 20/400 and with a greatest linear dimension of lesion over 450 microns were excluded from the study. Twenty-six eyes from 25 patients were treated with three consecutive intravitreal injections of pegaptanib (IVP group) and 55 eyes from 54 patients were treated with three consecutive ranibizumab injections (IVR group). Each therapy was repeated as needed. The alteration in BCVA was evaluated in the IVP and IVR groups.

\textbf{Results:} No differences were detected in baseline parameters between the IVP and IVR groups. The mean BCVA (logMAR) at month 1, 3, 6 and 12 after the initial treatment was improved from baseline in the IVP group (−0.095, −0.17, −0.18 and −0.18, respectively) and in the IVR group (−0.077, −0.15, −0.17 and −0.11, respectively), which was statistically significant. There was no difference in the change in mean BCVA between IVP and IVR groups at the same time periods.

\textbf{Conclusions:} The visual outcome of IVP was equivalent with IVR in exudative AMD with small lesion size.

\textbf{Keywords:} pegaptanib, ranibizumab, age-related macular degeneration, small lesion size

\section*{Introduction}

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agent is currently the main treatment for subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), a leading cause of central visual loss in the elderly in industrialized countries.\textsuperscript{1,2} Currently, there are two anti-VEGF agents approved to treat exudative (or neovascular) AMD; pegaptanib sodium, a specific anti-VEGF\textsubscript{165} aptamer and ranibizumab, a nonselective anti-VEGF-A antibody. Previous randomized control studies demonstrated a significant improvement in the mean visual acuity of exudative AMD patients treated with intravitreal injection of ranibizumab (IVR),\textsuperscript{3-5} while those treated with intravitreal injection of pegaptanib (IVP) showed no improvement in the mean visual acuity.\textsuperscript{6} However, recent reports documented that visual loss after 24 months of monthly IVR or at 24 months after IVR with a pro re nata (as needed) regimen was associated with abnormalities of retinal pigment epithelium (RPE), excessive subretinal fibrosis, and atrophic scar.\textsuperscript{7,8} We hypothesized that those results might be attributable to nonspecific suppression of VEGF, a potent survival factor for photoreceptor cells,\textsuperscript{9} choroidal vascular endothelial cells,\textsuperscript{10} and RPE\textsuperscript{11,12}
thus the subtype-specific anti-VEGF therapy should be selected as the main intervention to treat exudative AMD. To our knowledge, no study has been published to compare the effectiveness between IVP and IVR for exudative AMD with respect to lesion size.

In this study, we performed a comparative assessment to determine whether the visual outcomes of IVP and IVR were different in exudative AMD with relatively smaller lesion size and better baseline visual acuity.

**Subjects and methods**

The records of 185 consecutive exudative AMD patients treated by IVP or IVR and followed up over 12 months were retrospectively reviewed. All patients received detailed ophthalmic examinations, including best corrected visual acuity (BCVA) measurements, slit lamp biomicroscopy of their fundi, color fundus photography, fluorescein angiography (FA), indocyanine green angiography (ICG) and optical coherence tomography (OCT). Patients with baseline BCVA under 20/400, those with a greatest linear dimension (GLD) of lesion over 4500 µm, and patients who had received previous therapy for AMD were excluded from the study. Patients with past histories of retinal vessel occlusion, uveitis, rhegmatogenous retinal detachment or glaucoma were also excluded. Following these protocols, 81 eyes of 78 patients were included for analysis.

From October 2008 to March 2009, all patients were treated by IVP. After ranibizumab became available in Japan (April 2009), IVR was selected as the main intervention and IVP was used for patients with a risk of brain infarction. In the IVP group (26 eyes of 25 patients), all patients received three consecutive IVP injections at infarction. In the IVP group (26 eyes of 25 patients), prevention and IVP was used for patients with a risk of brain infarction. In the IVR group (26 eyes of 25 patients), all patients received three consecutive IVP injections at infarction. In the IVR group (26 eyes of 25 patients), all patients received three consecutive IVP injections at infarction. In the IVR group (26 eyes of 25 patients), all patients received three consecutive IVP injections at infarction. In the IVR group (26 eyes of 25 patients), all patients received three consecutive IVP injections at infarction.

For statistical analysis, we first compared gender, age, BCVA, GLD at baseline between the IVP and IVR groups. Changes in BCVA were then compared until 12 months after the initial treatment. Visual acuities were determined using a Landolt C chart, and were converted to logarithm of the minimum angle of resolution (logMAR) values for calculation. An F-test for homoscedasticity of variance followed by a two-tailed t-test or a chi-square test was performed to compare any two groups. P values of 0.05 or less were considered to be statistically significant.

**Results**

The data summary of AMD patients treated by IVP or IVR is shown in Table 1. No baseline parameter showed significant difference between the IVP and IVR groups. The F-test indicated homoscedasticity of variance in BCVA between the IVP and IVR groups (F-value = 0.49, P = 0.49). In the time course analysis, the mean BCVA was significantly improved compared with the baseline BCVA in each group (Figure 1). Although the IVR group showed a decrease in the mean BCVA at the 12 month follow-up, there was no significant difference between the IVP group and the IVR group at any time period measured. For BCVA measurements, about 25%–30% of patients gained more than 0.3 LogMAR during 12 months after the initial therapy, whereas about 10% of patients lost more than 0.3 LogMAR during the same time period in both groups (Figure 2). There was no significant difference in the proportion of BCVA change in the IVP

For statistical analysis, we first compared gender, age, BCVA, GLD at baseline between the IVP and IVR groups. Changes in BCVA were then compared until 12 months after the initial treatment. Visual acuities were determined using a Landolt C chart, and were converted to logarithm of the minimum angle of resolution (logMAR) values for calculation. An F-test for homoscedasticity of variance followed by a two-tailed t-test or a chi-square test was performed to compare any two groups. P values of 0.05 or less were considered to be statistically significant.

**Table 1** Data summary of the participants treated by intravitreal injection of pegaptanib or ranibizumab

<table>
<thead>
<tr>
<th></th>
<th>IVP (n=26)</th>
<th>IVR (n=55)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female</td>
<td>19/6</td>
<td>35/18</td>
<td>0.37†</td>
</tr>
<tr>
<td>Age (years)</td>
<td>72.2 ± 11.0</td>
<td>74.3 ± 9.7</td>
<td>0.40*</td>
</tr>
<tr>
<td>Age range (years)</td>
<td>50–89</td>
<td>51–92</td>
<td></td>
</tr>
<tr>
<td>Lesion type (eyes)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predominantly classic</td>
<td>6</td>
<td>8</td>
<td>0.65†</td>
</tr>
<tr>
<td>Minimally classic</td>
<td>6</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Occult with no classic</td>
<td>4</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>With PCV</td>
<td>10</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Baseline BCVA (LogMAR)</td>
<td>0.44 ± 0.37</td>
<td>0.50 ± 0.36</td>
<td>0.49*</td>
</tr>
<tr>
<td>BCVA range</td>
<td>20/400–20/20</td>
<td>20/400–20/20</td>
<td></td>
</tr>
<tr>
<td>Baseline GLD (µm)</td>
<td>2337 ± 1014</td>
<td>2825 ± 912</td>
<td>0.10*</td>
</tr>
<tr>
<td>GLD range (µm)</td>
<td>686–4290</td>
<td>810–4232</td>
<td></td>
</tr>
<tr>
<td>Number of injections/year</td>
<td>4.6 ± 2.2</td>
<td>5.1 ± 2.3</td>
<td>0.39*</td>
</tr>
<tr>
<td>Number of injections/year range</td>
<td>3–9</td>
<td>3–11</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** Values are presented as mean ± SD when applicable. t-test or a chi-square test. 

**Abbreviations:** IVP, intravitreal injection of pegaptanib; IVR, intravitreal injection of ranibizumab; BCVA, best corrected visual acuity; GLD, greatest linear dimension; PCV, polypoidal choroidal vasculopathy.
that secondary visual loss, occurring at or after month 24 of IVR, was associated with abnormalities of the retinal pigment epithelium (RPE), subretinal fibrosis and atrophic scar, which suggested the risk of nonspecific suppression of VEGF by ranibizumab. Efforts were made to decrease the number of IVR injections to treat exudative AMD, but the use of IVP may be considered as an alternative therapy for exudative AMD with small lesion size. VEGF165 is known as the major inducer of abnormal blood vessel growth and leakage in wet AMD, but all VEGF-A isoforms are key angiogenic and neuroprotective factors for several tissues. Nonspecific inhibition of all VEGF-A isoforms might reduce the ability to tolerate several kinds of stresses in the photoreceptor, RPE and normal choroidal endothelial cells. The abnormalities of RPE and atrophic scars found in the cases treated with monthly IVR might reflect the lack of VEGF-mediated neuroprotection for the cells. Interestingly, we found that four cases showed atrophic scars and three cases showed subfoveal fibrosis in the IVR group, whereas those findings were not observed in the IVP group in the present study. To avoid the risk of oversuppression of physiological VEGF effects, many studies have been conducted to reduce the number of IVR injections. A recent prospective study has demonstrated good visual outcomes of exudative AMD patients by using IVP as a maintenance therapy after IVR. Other studies reported that good visual stability was obtained with IVP monotherapy in selective cases, particularly those in the early stage. Since the pathogenesis of CNV is thought to be associated with VEGF165 and VEGF121, IVP monotherapy may not be sufficient to suppress all CNV. However, our results have demonstrated that IVP could be a useful modality of choice for patients with exudative AMD having small lesion size.

The major limitation of the present study was the non-randomized and retrospective nature of the study and the relatively small number of subjects. Hence, it is important to evaluate the results of randomized control trials for IVP and IVR with a large number of subjects to determine the comparative effectiveness of these therapies, particularly for exudative AMD with small lesion size. Further investigations will be needed to determine the correct indications for use of IVP and IVR for exudative AMD.

In conclusion, IVP may be an effective therapy for BCVA over a 12 month period in patients with exudative AMD and lesions less than 4500 µm in size.

**Acknowledgments**

This study was supported by Grant-in-Aid (C) 23592567 from the Ministry of Education, Science, and Culture.
Tokyo, Japan (S.H.), and by a grant from the Takeda Science Foundation (S.H.). The funding organizations had no role in the design or conduct of this research.

Disclosure
The authors report no conflicts of interest in this work.

References